Ennov Announces Strategic Growth Investment from Bregal Sagemount and Ardian
20.5.2026 14:00:00 CEST | Business Wire | Press Release
Ennov (the “Company”), a global provider of end-to-end regulatory, quality, and clinical software solutions for life sciences and healthcare companies, today announced a strategic growth investment led by Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm, with participation from Ardian, a global private investment firm. The investment will support the Company’s continued expansion, with a focus on AI innovation, global go-to-market acceleration, and scaling its product offering.
Founded and headquartered in Paris, Ennov provides a unified compliance platform that serves as a centralized system of record for global life sciences organizations. The platform supports the management of content and data across key domains, including Regulatory, Quality, Commercial, Clinical, and Pharmacovigilance. Its integrated architecture and unified data model enable faster deployment, improved user adoption, consistent compliance, and AI-driven efficiency across global operations.
Developed over more than 25 years, Ennov’s software replaces fragmented point solutions and legacy infrastructure, enabling customers to manage complex regulatory requirements across global authorities such as the FDA and EMA within a single system. Today, the Company serves approximately 650 customers and over 500,000 users across 30 countries.
“We were looking for partners who understand the complexity of our customers’ environments and the opportunity ahead for integrated and AI-enabled software in life sciences,” said Olivier Pâris, Founder and CEO of Ennov. “Sagemount and Ardian bring that perspective, and we look forward to continuing to build innovative solutions that support our customers’ most critical processes.”
“Regulatory and quality workflows in life sciences are becoming increasingly complex, while the cost of managing them across disconnected systems continues to rise,” added Gene Yoon, Managing Partner at Sagemount. “Olivier and his team have spent more than two decades building a mission-critical solution that enables customers to not only manage but optimize their processes to achieve better business outcomes. We believe this opportunity is only accelerating with Ennov’s new AI products, and we’re excited to support the Company in its next phase of growth.”
“Ennov represents exactly the kind of technology company we seek to support at Ardian Growth. We are excited to join forces with Bregal Sagemount, bringing together two leading US and European investment firms behind an exceptional management team,” added Alexis Saada, Head of Growth at Ardian. “With its strong international footprint and rapidly expanding AI capabilities, Ennov is uniquely positioned to shape the future of regulatory, quality, and clinical software in life sciences worldwide.”
With this growth investment, Gene Yoon, Curt Witte, and Harrison Brunelli from Sagemount and Alexis Saada from Ardian will be joining Ennov’s board of directors.
Ennov was advised by Veil Jourde. Sagemount was advised by Goodwin Procter LLP. Ardian was advised by Proskauer Rose LLP.
The transaction is expected to close in late Q2 2026, subject to regulatory approvals and customary closing conditions.
About Ennov:
Ennov provides a comprehensive software platform to manage the most demanding processes of life sciences organizations in a compliant and efficient way. With over 25 years of experience, Ennov’s cloud-based solutions cover Regulatory Affairs, Pharmacovigilance, Quality, Clinical, and Commercial. Dedicated to innovation and excellence, Ennov’s solutions are used by more than 650 companies and 500,000 users worldwide, helping them to bring their products to market faster while maintaining compliance with regulatory requirements. For more information, visit en.ennov.com or follow us on LinkedIn.
About Bregal Sagemount:
Bregal Sagemount is a leading growth-focused private capital firm with $11 billion of cumulative capital raised. The firm provides flexible capital and strategic assistance to market-leading companies in high-growth sectors across a wide variety of transaction situations. Bregal Sagemount has invested in over 90 companies in a variety of sectors, including software, data & information services, financial technology & services, digital infrastructure, healthcare IT, and business & consumer services. The firm has offices in New York and Palo Alto. For more information, visit www.sagemount.com or follow us on LinkedIn.
About Ardian:
In a world of constant evolution, Ardian stands out for its ability to anticipate, adapt, and turn challenges into opportunities. As a global, diversified private markets firm with 22 offices and more than 350 investment professionals worldwide, we provide investment and customized solutions that reflect new economic dynamics and help our clients remain resilient in a changing world. We deliver multi-local expertise and long-term performance for our investors and partners as well as shared value for the broader society. Since Ardian’s inception in 1996, our pioneering approach to diversification and our ability to offer tailor-made solutions at scale have remained the heart of our strategy. Through commitment, knowledge and technology, we bring lasting value to our companies and contribute positively to the whole industry. Ardian currently manages or advises $200bn for more than 1,920 clients worldwide across Private Equity, Real Assets, and Credit. Ardian. Mastering change for lasting value. For more information, visit ardian.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260518090659/en/
Contacts
Ennov
Laure Bros
Chief Sales and Marketing Officer
lbros@ennov.com
Bregal Sagemount
Siqi Wu
Marketing & Communications Manager
Siqi.wu@bregal.com
Ardian
HEADLAND
ardian@headlandconsultancy.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom